Tags : Spark

PharmaShots Weekly Snapshots (October 11 – 15, 2021)

Tuba Khan October 15, 2021

Bristol Myers Squibb’s Zeposia (ozanimod) Receives CHMP’s Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis Published: 15 Oct, 2021 | Tags: Bristol Myers Squibb, Zeposia, ozanimod, […]readmore

Biotech

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for

Tuba Khan October 13, 2021

Shots: Spark to get exclusive, WW license to develop, manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program The companies will work together and […]readmore

Tags : Spark

PharmaShots Weekly Snapshots (October 11 – 15, 2021)

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Spark

PharmaShots Weekly Snapshots (October 11 – 15, 2021)

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company